The researchers concluded that the two-dose vaccine regimen effectively reduced E. coli O157:H7 fecal shedding and hide contamination, and that vaccination of cattle within regions of the feedyard provided greater protection against hide contamination than commingling vaccinates and non-vaccinates.
The second article, entitled, "Escherichia coli O157:H7 Vaccine Dose-Effect in Feedlot Cattle", was co-authored by Rodney A. Moxley, David R. Smith, Matt Luebbe, Galen E. Erickson, Terry J. Klopfenstein, and Dragan Rogan.
This article summarized a clinical trial conducted in 2006, which evaluated the effects of two- and three-dose regimens of the Econiche vaccine on the probability of detecting E. coli O157:H7 in feces and colonization of the terminal rectum.
The researchers concluded that the three-dose regimen significantly reduced the probability for cattle to shed E. coli in feces 65% compared to placebo-treated cattle. A dose-effect was demonstrated because a two-dose regimen of the vaccine product was intermediate in effect. These results are consistent with previous estimates of vaccine efficacy against fecal shedding, and agree with the researchers' previous finding that efficacy of two or three doses of the vaccine exhibit a dose response.
"These two peer-reviewed publications further substantiate the efficacy of Econiche," said Dr. Dragan Rogan, Vice-President, Animal Health Research Development at Bioniche Life Sciences Inc. "Not only has the vaccine substantially reduced the amount of E. coli O157 shed by cattle into the environment, it has reduced the likelihood that cattle are colonized by
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2009 PR Newswire.
All rights reserved